7
|
Hall KT, Nelson CP, Davis RB, Buring JE, Kirsch I, Mittleman MA, Loscalzo J, Samani NJ, Ridker PM, Kaptchuk TJ, Chasman DI. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34:2160-7. [PMID: 25035343 PMCID: PMC4148908 DOI: 10.1161/atvbaha.114.303845] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2014] [Accepted: 06/25/2014] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Catechol-O-methyltransferase (COMT), a key enzyme in catecholamine metabolism, is implicated in cardiovascular, sympathetic, and endocrine pathways. This study aimed to confirm preliminary association of COMT genetic variation with incident cardiovascular disease (CVD). It further aimed to evaluate whether aspirin, a commonly used CVD prevention agent, modified the potential association of COMT with incident CVD. APPROACH AND RESULTS We examined COMT polymorphism rs4680 (MAF [minor allele frequency], 0.47), encoding a nonsynonymous methionine-to-valine substitution, in the Women's Genome Health Study (WGHS), a large population-based cohort of women with randomized allocation to aspirin or vitamin E when compared with placebo and 10-year follow-up. Rs4680 effects were confirmed with COMT polymorphism rs4818 and also examined in Coronary ARtery DIsease Genome-wide Replication and Meta-analysis/The Coronary Artery Disease Genetics Consortium, consortia for genome-wide association studies of coronary artery disease. Among WGHS women allocated to placebo (135 events/n=5811), the rs4680 valine allele was protective against incident CVD relative to the methionine (hazard ratio [HR; 95% confidence interval {CI}], 0.66 [0.51-0.84]; P=0.0007); an association also observed in Coronary ARtery DIsease Genome-wide Replication and Meta-analysis and The Coronary Artery Disease Genetics Consortium (combined P=2.4×10(-5)). In the WGHS, the rs4680 association was abolished by randomized allocation to aspirin, such that valine/valine women experienced higher CVD rates with aspirin allocation when compared with placebo (HR [95% CI], 1.85 [1.05-3.25]; P=0.033), whereas methionine/methionine women experienced lower rates (HR [95% CI], 0.60 [0.39-0.93]; P=0.023). Allocation to vitamin E also conferred higher but nonsignificant CVD rates on valine/valine (HR [95% CI], 1.50 [0.83-2.70]; P=0.180) when compared with significantly lower rates on methionine/methionine (HR [95% CI], 0.53 [0.34-0.84]; P=0.006) women. Rs4818 results were similar. CONCLUSIONS Common COMT polymorphisms were associated with incident CVD, and this association was modified by randomized allocation to aspirin or vitamin E. Replication of these findings is required.
Collapse
Affiliation(s)
- Kathryn T Hall
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.).
| | - Christopher P Nelson
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Roger B Davis
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Julie E Buring
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Irving Kirsch
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Murray A Mittleman
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Joseph Loscalzo
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Nilesh J Samani
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Paul M Ridker
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Ted J Kaptchuk
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| | - Daniel I Chasman
- From the Program in Placebo Studies, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular Sciences, Clinical Research Centre, Glenfield General Hospital, University of Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard School of Public Health Boston, MA (M.A.M.)
| |
Collapse
|
18
|
Gupta M, Chauhan C, Bhatnagar P, Gupta S, Grover S, Singh PK, Purushottam M, Mukherjee O, Jain S, Brahmachari SK, Kukreti R. Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 2009; 10:277-91. [DOI: 10.2217/14622416.10.2.277] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychotic therapy. Materials & methods: Single-locus association analyses of these polymorphisms were carried out in 254 patients with schizophrenia and 225 controls, all of southern Indian origin. Additionally, multifactor-dimensionality reduction analysis was performed in 422 samples (243 cases and 179 controls) to examine the gene–gene interactions and to identify combinations of multilocus genotypes associated with either high or low risk for the disease. Results: Our results demonstrated initial significant associations of two SNPs for DRD2 (rs11608185, genotype: χ2 = 6.29, p-value = 0.043; rs6275, genotype: χ2 = 8.91, p-value = 0.011), and one SNP in the COMT gene (rs4680, genotype: χ2 = 6.67, p-value = 0.035 and allele: χ2 = 4.75, p-value = 0.029; odds ratio: 1.33, 95% confidence interval: 1.02–1.73), but not after correction for multiple comparisons indicating a weak association of individual markers of DRD2 and COMT with schizophrenia. Multifactor-dimensionality reduction analysis suggested a two locus model (rs6275/DRD2 and rs4680/COMT) as the best model for gene–gene interaction with 90% cross-validation consistency and 42.42% prediction error in predicting disease risk among schizophrenia patients. Conclusion: The present study thus emphasizes the need for multigene interaction studies in complex disorders such as schizophrenia and to understand response to drug treatment, which could lead to a targeted and more effective treatment.
Collapse
Affiliation(s)
- Meenal Gupta
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | - Chitra Chauhan
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | - Pallav Bhatnagar
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | - Simone Gupta
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | - Sandeep Grover
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | - Prashant K Singh
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | | | - Odity Mukherjee
- National Institute of Mental Health and Neuro Sciences, India
| | - Sanjeev Jain
- National Institute of Mental Health and Neuro Sciences, India
| | - Samir K Brahmachari
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| | - Ritushree Kukreti
- Functional Genomics Unit, Institute of Genomics and Integrative Biology (Council of Scientific and Industrial Research), Mall Road, Delhi 110 007, India
| |
Collapse
|